- Home
- ACLX
ACLX
Arcellx Inc.
as 01-17-2025 4:00pm EST
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 5.3B | IPO Year: | 2022 |
| Target Price: | $107.67 | AVG Volume (30 days): | 695.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $47.88 - $107.37 | Next Earning Date: | 02-26-2025 |
| Revenue: | $155,818,000 | Revenue Growth: | 230.33% |
| Revenue Growth (this year): | 12.58% | Revenue Growth (next year): | -2.75% |
Stock Insider Trading Activity of Arcellx Inc. (ACLX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Heery Christopher | ACLX | CHIEF MEDICAL OFFICER | Jan 7 '25 | Sell | $74.61 | 7,783 | $581,315.58 | 28,638 | |
| Elghandour Rami | ACLX | SEE REMARKS | Jan 7 '25 | Sell | $74.61 | 30,311 | $2,263,941.87 | 131,112 | |
| Gilson Michelle | ACLX | CHIEF FINANCIAL OFFICER | Jan 2 '25 | Sell | $78.36 | 11,243 | $880,974.00 | 27,591 | |
| Heery Christopher | ACLX | CHIEF MEDICAL OFFICER | Jan 2 '25 | Sell | $78.36 | 18,674 | $1,463,818.53 | 28,638 | |
| Elghandour Rami | ACLX | SEE REMARKS | Jan 2 '25 | Sell | $78.36 | 58,856 | $4,613,094.36 | 131,112 | |
| Patel Kavita | ACLX | Director | Dec 24 '24 | Sell | $77.27 | 1,500 | $115,450.54 | 100 | |
| Patel Kavita | ACLX | Director | Dec 3 '24 | Sell | $92.02 | 1,500 | $137,817.72 | 100 | |
| Gilson Michelle | ACLX | CHIEF FINANCIAL OFFICER | Nov 15 '24 | Sell | $90.93 | 1,761 | $156,508.43 | 27,591 | |
| Patel Kavita | ACLX | Director | Nov 12 '24 | Sell | $106.33 | 1,500 | $159,495.00 | 100 | |
| Gilson Michelle | ACLX | CHIEF FINANCIAL OFFICER | Nov 8 '24 | Sell | $101.29 | 12,354 | $1,242,170.45 | 27,591 |
Latest Arcellx Inc. News
ACLX Breaking Stock News: Dive into ACLX Ticker-Specific Updates for Smart Investing
Zacks
3 days ago
Adaptive Biotechnologies (ADPT) Soars 18.0%: Is Further Upside Left in the Stock?
Argus Research
6 days ago
Daily – Vickers Top Buyers & Sellers for 01/13/2025
MT Newswires
6 days ago
Arcellx Insider Sold Shares Worth $2,263,942, According to a Recent SEC Filing
MT Newswires
6 days ago
Arcellx Insider Sold Shares Worth $1,355,024, According to a Recent SEC Filing
Zacks
12 days ago
Guardant Health (GH) Soars 6.3%: Is Further Upside Left in the Stock?
MT Newswires
12 days ago
Arcellx Insider Sold Shares Worth $2,244,896, According to a Recent SEC Filing
Investor's Business Daily
22 days ago
Arcellx Stock Earns 82 Relative Strength Rating
Clinical Trials Arena
a month ago
ASH 2024: Arcellx publishes positive results for Anito-cel in multiple myeloma
Compare ACLX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACLX Arcellx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.